A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Basit Öğe Kaydı
dc.authoridKARAAGAC, MUSTAFA/0000-0003-4533-0620
dc.authoridKilickap, Saadettin/0000-0003-1637-7390
dc.authoridYasar, Hatime/0000-0002-0545-1383
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorOzturk, Akin
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorCicin, Irfan
dc.contributor.authorPaydas, Semra
dc.date.accessioned2025-02-22T14:08:53Z
dc.date.available2025-02-22T14:08:53Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractTo evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2-16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers-a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics.en_US
dc.identifier.doi10.1097/MD.0000000000037972
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue21en_US
dc.identifier.pmid38787994en_US
dc.identifier.scopus2-s2.0-85194219961en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000037972
dc.identifier.urihttps://hdl.handle.net/11468/29697
dc.identifier.volume103en_US
dc.identifier.wosWOS:001230616700060
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofMedicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectImaging Characteristicsen_US
dc.subjectGene Rearrangementen_US
dc.subjectAdenocarcinomasen_US
dc.subjectManagementen_US
dc.subjectFusionen_US
dc.titleA multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu